<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5032">
  <stage>Registered</stage>
  <submitdate>27/02/2015</submitdate>
  <approvaldate>27/02/2015</approvaldate>
  <nctid>NCT02386553</nctid>
  <trial_identification>
    <studytitle>A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy</studytitle>
    <scientifictitle>An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy.</scientifictitle>
    <utrn />
    <trialacronym>NURTURE</trialacronym>
    <secondaryid>2014-002098-12</secondaryid>
    <secondaryid>232SM201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Spinal Muscular Atrophy</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nusinersen

Experimental: Nusinersen - Nusinersen administered as an intrathecal injection


Treatment: drugs: Nusinersen
Solution for intrathecal injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to death or respiratory intervention - The time will be the age of the participant at the first occurrence of either a respiratory intervention or death. Respiratory intervention is defined as invasive or noninvasive ventilation for =6 hours/day continuously for 7 or more days OR tracheostomy.</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants developing clinically manifested spinal muscular atrophy (SMA).</outcome>
      <timepoint>At 13 and 24 months of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants alive</outcome>
      <timepoint>At 13 months, and 2, 3, 4 and 5 years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE)</outcome>
      <timepoint>At 13 and 24 months of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria</outcome>
      <timepoint>At 13 and 24 months of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in weight for age/length</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in head circumference</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in chest circumference ratio</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in head to chest circumference ratio</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in arm circumference ratio</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events (AEs) and/or serious adverse events (SAEs)</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in clinical laboratory parameters - Assessed by the following laboratory tests: Hematology: red blood cells, hemoglobin, hematocrit, platelets, white blood cells, white blood cell differential, Blood chemistry: total protein, albumin, creatinine, cystatin C, creatine phosphokinase, blood urea nitrogen, total bilirubin (direct and indirect), alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, glucose, calcium, phosphorous, chloride, sodium, potassium. Urinalysis: specific gravity, pH, protein, glucose, ketones, bilirubin, red blood cells, white blood cells, epithelial cells, bacteria, casts, crystals</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in electrocardiograms (ECGs)</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in vital signs - Vital sign will be assessed by: temperature, pulse rate, resting systolic and diastolic blood pressure, and respiratory rate.</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in neurological examinations</outcome>
      <timepoint>Up to Day 1820</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations.</outcome>
      <timepoint>Up to Day 1730</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Age = 6 weeks at first dose

          -  Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound
             heterozygous mutation.

          -  Genetic documentation of 2 or 3 copies of survival motor neuron 2 (SMN2).

          -  Ulnar compound muscle action potential (CMAP) = 1 mV at Baseline.

          -  Gestational age of 37 to 42 weeks for singleton births; gestational age of 34 to 42
             weeks for twins.

          -  Meet additional study related criteria.

        Key</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>6</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Hypoxemia (oxygen saturation &lt;96% awake or asleep without any supplemental oxygen or
             respiratory support).

          -  Any clinical signs or symptoms at Screening or immediately prior to the first dosing
             (Day 1) that are, in the opinion of the Investigator, strongly suggestive of SMA.

          -  Clinically significant abnormalities in hematology or clinical chemistry parameters.

          -  Treatment with an investigational drug given for the treatment of SMA biological
             agent, or device. Any history of gene therapy, prior antisense oligonucleotide (ASO)
             treatment, or cell transplantation.

          -  Meet additional study related criteria.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Prevention</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>20/05/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>26/01/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Children's Hospital- Melbourne - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-WÃ¼rttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Qatar</country>
      <state>Doha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Sihhiye</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen
      administered intrathecally in preventing or delaying the need for respiratory intervention or
      death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA).
      Secondary objectives of this study are to examine the effects of Nusinersen in infants with
      genetically diagnosed and presymptomatic SMA.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02386553</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Biogen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>